What Happened

Enliven Therapeutics announced positive Phase 1 data for ELVN-001, a kinase inhibitor targeting CML, showing 61% overall MMR in the 80 mg QD cohort. The FDA aligned with Enliven on the Phase 3 dose and patient population, paving the way for the ENABLE-2 trial to begin in late 2026.

Who Is Affected

This development impacts hematologists, oncologists, and CML patients, particularly those who have failed prior TKI therapies. The data highlights ELVN-001's efficacy in heavily pretreated patients, including those resistant to asciminib.

Market Impact

• ELVN-001 could disrupt the CML treatment landscape as a best-in-class ATP-competitive inhibitor.
• The FDA alignment accelerates the path to Phase 3, creating urgency for stakeholders.
• Enliven's progress may pressure competitors in the TKI market.

What to Watch

Monitor the initiation of the ENABLE-2 trial in late 2026 and further updates on ELVN-001's safety and efficacy. Key milestones include regulatory submissions and potential partnerships or commercialization strategies.